JUNE

Month At Glance

Pharmaceuticals and Healthcare

NEWS ROUND UP
Pharma gets what it bargained for rials to all generic manufacturers servicing GSK again extends its $2.6 billion the US market, which is the most lucrative bid for HGS in U.S. Supreme Court ruling
Analysis points to expanded patient base, 12 years of biosimilar exclusivity, and more fees. The new bill has allowed 12 years exclusivity on biosimilars.Also they wont be discounted like small-molecule generics. Also more people on insurance provides a greater market for the expensive drugs. Most states are expected to go in for the medicaid program which means more patients for the drug companies. of all global markets

Indias A Major Source Of Innovation In Healthcare Delivery

At present, the Indian health sector represents a total value of about $65 billion. India's in the world's top three countries with the strongest growth of investments in this field. India also has a rapidly growing $5 billion market of medical and technological products. The life sciences and health sector has a turnover of around $4 billion, showing more than 20% growth over the past few years.

GlaxoSmithKline ($GSK) has again extended its $2.6 billion offer to buy its now estranged development partner Human Genome Sciences ($HGSI), giving shareholders until July 20 to offer up their shares

Piramal Acquires Decision Resources Group, US Analytics Company, For $635 mn

The purchase, which will cost Piramal Healthcare $635 million, will help the company's nascent drug discovery business predict emerging trends and change its product portfolio accordingly.

Indian Pharma Companies Like Hetero, Alembic, Lupin, Dr Reddys Dominating US Generic New Study Shows Japan Most Possible Nexus Between Pharma Space India is playing a dominant role in the US Expensive For Investing In Clini- Firms, DCGI Officials: generic pharma space, having cornered cal Trials, Followed By Australia A parliamentary panel has indicated a possiover half the certified dossiers filed globally for active pharmaceutical ingredients (API). Drug companies from India filed 51% of the overall global applications, also called drug master filings (DMF), in the US market during calendar year 2011. DMFs are essentially approvals to supply complex raw mateA new international report on the global competitiveness of 14 countries has ranked Japan competitive as the most expensive market for clinical trial investment, closely followed by Australia. India and China were ranked as the more favorable nations for investing. ble nexus between pharma companies, some officials at the Drug Controller General of India and the independent medical experts who have a crucial role in determining whether a drug should be allowed in market.

Special Focus : India to begin paying for drugs for 'everyone'

Currently, Indian patients needing healthcare, including drugs, have to pay nearly 80% of the cost out of their own pockets. According to Pharma Times, India is going to make 350 drugs available free to everyone who needs them beginning in October. It has already set aside $17.5 million to pay for nearly drugs in the next fiscal year. The federal government will cover 75% of the cost and states are expected to pick up the rest. While the amount of money allocated seems small for a country with a population like India's, this falls in line with what many in the pharmaceutical industry have been saying needs to happen rather than stripping branded drug makers of their patent protection to make drugs more affordable. The story says the government will buy directly from manufacturers and importers but set up some requirements to qualify

Industry Talk
We are considering a proposal of venture capital fund of Rs 2,000 crore for the drugs industry. We are talking with Exim Bank for this. He said it was the entry of Indian generic medicines in the global supply chain which started an ethical debate worldwide on generics versus patented drugs, and ultimately the right of every citizen to access affordable quality medicines were upheld. While time and again there have been attempts by multinationals to malign Indian generics as substandard, counterfeit, the resilience of Indian industry has withstood all these challenges.
Anand Sharma Commerce and Industry minister